HK1221952A1 - 作為 蛋白和極體樣激酶的雙重抑制劑的取代的二氫吡啶並 吡嗪酮 - Google Patents
作為 蛋白和極體樣激酶的雙重抑制劑的取代的二氫吡啶並 吡嗪酮Info
- Publication number
- HK1221952A1 HK1221952A1 HK16110129.5A HK16110129A HK1221952A1 HK 1221952 A1 HK1221952 A1 HK 1221952A1 HK 16110129 A HK16110129 A HK 16110129A HK 1221952 A1 HK1221952 A1 HK 1221952A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bet
- pyrazinones
- polo
- kinases
- dual inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13177539 | 2013-07-23 | ||
PCT/EP2014/065605 WO2015011084A1 (de) | 2013-07-23 | 2014-07-21 | Substituierte dihydropyrido[3,4-b]pyrazinone als duale inhibitoren von bet-proteinen und polo-like kinasen |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1221952A1 true HK1221952A1 (zh) | 2017-06-16 |
Family
ID=48832802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16110129.5A HK1221952A1 (zh) | 2013-07-23 | 2016-08-25 | 作為 蛋白和極體樣激酶的雙重抑制劑的取代的二氫吡啶並 吡嗪酮 |
Country Status (8)
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
KR20150096794A (ko) | 2012-12-21 | 2015-08-25 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물 |
CN109939113B (zh) | 2013-06-21 | 2022-02-15 | 恒翼生物医药科技(上海)有限公司 | 双环溴结构域抑制剂 |
US9636328B2 (en) | 2013-06-21 | 2017-05-02 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
CA2919948C (en) | 2013-07-31 | 2020-07-21 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
WO2016087936A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridinones as bromodomain inhibitors |
CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
EP3233846A4 (en) | 2014-12-17 | 2018-07-18 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
EP3270917A4 (en) | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
WO2016207345A1 (en) * | 2015-06-24 | 2016-12-29 | Pierre Fabre Medicament | 3-amino-pyrazin-2-yl carboxamide and 2-amino-pyridin-3-yl carboxamide derivatives as polo-like kinase 1 (plk-1) inhibitors for the treatment of cancer |
CA2995036A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
KR101796779B1 (ko) | 2015-12-22 | 2017-11-10 | 한국화학연구원 | 다이하이드로프테리딘-온 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
EP4119552A1 (en) | 2017-02-08 | 2023-01-18 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
CN106977584B (zh) * | 2017-04-19 | 2019-12-06 | 吉林大学 | 靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
WO2018207881A1 (ja) * | 2017-05-12 | 2018-11-15 | 武田薬品工業株式会社 | 複素環化合物 |
WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
AU2019251223A1 (en) | 2018-04-13 | 2020-11-26 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
CN109096276B (zh) * | 2018-08-01 | 2021-05-28 | 上海博志研新药物技术有限公司 | 盐酸莫西沙星及其中间体的制备方法 |
WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
PE20221582A1 (es) | 2019-12-19 | 2022-10-06 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de receptor de androgenos |
CN115947728B (zh) * | 2021-10-09 | 2024-01-09 | 沈阳药科大学 | 含磺酰基的二氢喋啶酮衍生物及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
EP1784406A1 (de) * | 2004-08-27 | 2007-05-16 | Boehringer Ingelheim International GmbH | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
US20110207796A1 (en) * | 2008-02-13 | 2011-08-25 | Elan Pharma International Limited | Alpha-synuclein kinase |
WO2011143651A1 (en) * | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating metabolism |
US9249161B2 (en) * | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
EP2776444A4 (en) * | 2011-11-10 | 2015-07-22 | Osi Pharmaceuticals Llc | dihydropteridinones |
-
2014
- 2014-07-21 US US14/907,367 patent/US20160272635A1/en not_active Abandoned
- 2014-07-21 CN CN201480052256.5A patent/CN105555786A/zh active Pending
- 2014-07-21 CA CA2918813A patent/CA2918813A1/en not_active Abandoned
- 2014-07-21 EP EP14744029.1A patent/EP3027614B1/de not_active Not-in-force
- 2014-07-21 WO PCT/EP2014/065605 patent/WO2015011084A1/de active Application Filing
- 2014-07-21 JP JP2016528479A patent/JP2016525135A/ja not_active Withdrawn
- 2014-07-21 ES ES14744029.1T patent/ES2648876T3/es active Active
-
2016
- 2016-08-25 HK HK16110129.5A patent/HK1221952A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3027614B1 (de) | 2017-08-23 |
JP2016525135A (ja) | 2016-08-22 |
US20160272635A1 (en) | 2016-09-22 |
CA2918813A1 (en) | 2015-01-29 |
WO2015011084A1 (de) | 2015-01-29 |
CN105555786A (zh) | 2016-05-04 |
EP3027614A1 (de) | 2016-06-08 |
ES2648876T3 (es) | 2018-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1221952A1 (zh) | 作為 蛋白和極體樣激酶的雙重抑制劑的取代的二氫吡啶並 吡嗪酮 | |
ZA202001242B (en) | Tricyclic heterocycles as bet protein inhibitors | |
HK1223617A1 (zh) | 作為 蛋白抑制劑的三環雜環 | |
HK1217198A1 (zh) | 蛋白激酶抑制劑 | |
HK1215578A1 (zh) | 作為蛋白激酶抑制劑的氮雜吲哚衍生物 | |
EP2999702A4 (en) | Substituted pyrazolopyrimidines as kinases inhibitors | |
IL269170B (en) | The hemisulfate salt of tetrahydrofolic acid 5, 10 methylene (6r) | |
EP3065549A4 (en) | Methods for inhibiting tie2 kinase useful in the treatment of cancer | |
HK1219057A1 (zh) | 大環的鹽可誘導的激酶抑制劑 | |
EP3008161A4 (en) | Barley with very low levels of hordeins | |
EP3071572A4 (en) | Protein kinase inhibitors | |
EP3074401A4 (en) | Protein kinase inhibitors | |
EP3071573A4 (en) | Protein kinase inhibitors | |
AU2013902565A0 (en) | Barley with very low levels of hordeins | |
AU2013902140A0 (en) | Barley with very low levels of hordeins | |
GB201309603D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201305741D0 (en) | Novel compounds and their use as kinase inhibitors |